Clinical trial NCT03588078: Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
Official title: A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of Mutation TP53 (TP53) Mutant Myeloid Neoplasms
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Myelodysplastic Syndrome With Gene Mutation
Acute Myeloid Leukemia With Gene Mutations
Myeloproliferative Neoplasm
Chronic Myelomonocytic Leukemia
Keywords: Azacitidine
Lead sponsor: Groupe Francophone des Myelodysplasies
Sponsor class: OTHER
Collaborators: name: Aprea Therapeutics
First posted: 2018-07-17
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Participants will receive one dose of protocol therapy
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to determine the safe and efficacy of APR-246 in combination with azacitidine as well as to see complete remission of this patients

Detailed description: Patients will be treated for a total of 6 cycles.For patients responding or who have stable disease following cycle 6, treatment may continue until one of the following criteria applies:

* Inter-current illness that prevent further administration of treatment
* Unacceptable adverse event(s)
* Participant decides to withdraw from the study,
* general or specific changes in the participant's condition render the participant unacceptable for further treatment in the judgment of the investigator.
* Evidence of disease progression by international working Group (IWG) 2006 criteria.
* participants who wish not to continue treatment at time of disease assessment at end of cycle 6 will complete their end of treatment visit upon completion of cycle 6

Eligibility criteria: Inclusion Criteria:

1. Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements.
2. Patient has adequate organ function as defined by the following laboratory values:

   1. Serum creatinine ≤ 2 x upper limit of normal (ULN)
   2. Total serum bilirubin \< 1.5 x ULN or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert's Syndrome or hemolysis or who required regular blood transfusions
   3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN
3. Age ≥18 years at the time of signing the informed consent form
4. Documented diagnosis of myelodysplastic syndrome (MDS), MDS/ myeloproliferative neoplasm (MPN), chronic myelomonocytic leukemia (CMML) by World Health organization (WHO) criteria or non-proliferative AML (ie with WBC \< 20 G/l)
5. Documentation of a TP53 gene mutation by next-generation sequencing (NGS) based on central or local evaluation.
6. Revised International Prognostic Scoring System (IPSS-R) criteria for Intermediate, High-risk or Very High-risk.
7. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 is required.
8. If of childbearing potential, negative pre-treatment urine or serum pregnancy test.
9. If of childbearing potential (males and females), willing to use an effective form of contraception such as latex condom, hormonal birth control, intrauterine device or double barrier method during chemotherapy treatment and for at least six months thereafter.

Exclusion Criteria:

1. Patient has a known history of HIV or active hepatitis B or active hepatitis C infection (testing not mandatory).
2. Patient has any of the following cardiac abnormalities (as determined by treating MD):

   1. symptomatic congestive heart failure
   2. myocardial infarction ≤ 6 months prior to enrollment
   3. unstable angina pectoris
   4. serious uncontrolled cardiac arrhythmia
   5. QTc ≥ 470 msec (≥ 500 msec in the presence of RBBB) calculated from a mean of 3 ECG readings using Fridericia's correction (QTcF = QT/RR0.33)
   6. bradycardia (\<40 bpm)
   7. known left ventricular ejection fraction (LVEF) \< the institution lower limit of normal as assessed by ECHO
   8. clinically significant pericardial disease
   9. electrocardiographic evidence of acute ischemia
   10. familial history of long QT syndrome
3. Concomitant malignancies or previous malignancies with less than a 1-year disease free interval at the time of signing consent. Patients with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis.
4. Prior exposure to azacitidine, decitabine or investigational hypomethylating agent
5. Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of MDS, MDS/MPN, CMML or AML within 14 days of the first day of study drug treatment.
6. No concurrent use of erythroid stimulating agents, Granulocyte-colony stimulating Factor (G-CSF), Granulocyte Macrophage-colony stimulating factor (GM-CSF) is allowed during study except in cases of febrile neutropenia where G-CSF can be used for short term. Growth factors must be stopped 14 days prior to study.
7. Patients with history of allogeneic stem cell transplantation.
8. Pregnant women are excluded from this study because APR-246 has not been studied in pregnant subjects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with APR-246, breastfeeding should be discontinued if the mother is treated with APR-246.

Primary outcomes:
measure: Overall Survival
timeFrame: 8 months
Secondary outcomes:
measure: Duration of response
timeFrame: minimum 24 months it is defined as the time between achieving response and progression of disease
Other outcomes:
Locations:
city: Lille
country: France
facility: Bruno Quesnel
city: Nantes
country: France
facility: Dr Pierre Peterlin and Pr Patrice Chevalier
city: Nice
country: France
facility: Hôpital Archet 1
city: Paris
country: France
facility: Hôpital Saint Louis - Hématologie Séniors
city: Paris
country: France
facility: Hôpital Cochin/Service d'Hématologie
city: Rouen
country: France
facility: Aspasia Stamatoullas
city: Toulouse
country: France
facility: Odile Beyne Rosy
Study officials:
affiliation: service Hématologie Séniors Hôpital Saint Louis
name: Pierre Fenaux
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cluzeau T, Sebert M, Rahme R, Cuzzubbo S, Lehmann-Che J, Madelaine I, Peterlin P, Beve B, Attalah H, Chermat F, Miekoutima E, Rauzy OB, Recher C, Stamatoullas A, Willems L, Raffoux E, Berthon C, Quesnel B, Loschi M, Carpentier AF, Sallman DA, Komrokji R, Walter-Petrich A, Chevret S, Ades L, Fenaux P. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM). J Clin Oncol. 2021 May 10;39(14):1575-1583. doi: 10.1200/JCO.20.02342. Epub 2021 Feb 18.